WHO is convening a Guideline Development Group in December 2019, to assess available evidence on three molecular assays - Xpert, Xpert Ultra and Molbio TrueNat for the diagnosis of active TB (PTB and EPTB) and rifampicin-resistance in adults, adolescents and children with signs and symptoms of TB, as well as people being screened for TB.
In the interest of transparency regarding the ongoing development of guidelines, WHO is organizing an exceptional public comment process to share details about the preparatory work ahead of the update of the WHO TB diagnostic guidelines, and seeks comments on the scope of this work. Feedback can be submitted by registering here https://extranet.who.int/dataform/789325?lang=en by 26th September 2019.